This capstone unit develops the critical thinking needed to transform a new therapeutic drug or a device into a commercially viable product. Students will critically appraise scientific and clinical data and information to prepare the early-stage development, pre-clinical, clinical and regulatory strategies for approval by either the TGA or another regulatory jurisdiction, as well as the reimbursement submission strategy for Australia or relevant jurisdiction.
Unit details and rules
| Academic unit | Pharmacy |
|---|---|
| Credit points | 6 |
| Prerequisites
?
|
PHAR7816 and 12 credit points from (PHAR7817 or PHAR7818 or PHAR7823 or PHAR7825 or PHAR7826 or HPOL5014) |
| Corequisites
?
|
18 credit points of stream specific units of study |
|
Prohibitions
?
|
PCOL5104 |
| Assumed knowledge
?
|
None |
| Available to study abroad and exchange students | No |
Teaching staff
| Coordinator | Orin Chisholm, orin.chisholm@sydney.edu.au |
|---|---|
| Lecturer(s) | Philip Kwok, philip.kwok@sydney.edu.au |